PROTALIX BIOTHERAPEUTICS INC (PLX)
Health Care · Rare disease biopharmaceuticals / enzyme replacement therapy · Nyse Mkt Llc
A rare-disease biopharmaceutical company with a proprietary plant cell-based protein expression platform and two FDA/EMA-approved enzyme replacement therapies for lysosomal storage disorders.
What PROTALIX BIOTHERAPEUTICS INC does
Protalix Biotherapeutics is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapeutics for rare and orphan diseases. It operates a proprietary ProCellEx plant cell-based protein expression system, the first and only platform to achieve FDA approval for proteins produced through plant cell suspension culture. The company currently markets two enzyme replacement therapies (ERTs): Elelyso (taliglucerase alfa) for Gaucher disease and Elfabrio (pegunigalsidase alfa) for Fabry disease, while developing new candidates including PRX-115 (PEGylated uricase) for gout and PRX-119 (LA DNase I) for NET-related diseases.
Themes: ["Enzyme replacement therapy / lysosomal storage disorders","Rare and orphan diseases","Plant-based biotherapeutics / recombinant protein production","Gaucher disease","Fabry disease","Gout treatment","Protein modification / PEGylation"]
Fundamentals
- Price$2.37 as of 2026-07-09 close
- Market cap$195M as of 2026-07-10
- 1-year return+54.9% as of 2026-07-09 close
- P/E12.69 as of 2026-07-10
- Net margin+20.1% as of 2026-07-10
- Gross margin+70.0% as of 2026-07-10
- ROE+28.1% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+27.8% as of 2026-07-10
- Revenue CAGR (3y)+3.5% SEC XBRL
- Beta-0.00 as of 2026-07-10
Key risks (from latest filing)
["Dependence on partner commercialization: Elelyso revenues depend on Pfizer and Fiocruz order patterns, which may vary period-to-period and lack direct correlation to patient demand, creating revenue volatility.","Regulatory and clinical risk: Early-stage pipeline candidates (PRX-115, PRX-119) require successful Phase 2 and potentially Phase 3 trials and regulatory approval before generating meaningful revenue.","Limited market for approved products: Gaucher disease and Fabry disease are rare conditions with limited patient populations, constraining market size despite high disease burden."]
Competitors & peers
- Sanofi (SNYNFSMR) - markets Imiglucerase for Gaucher disease
- Genzyme Corporation (subsidiary of Sanofi) - alternative Gaucher treatments
- Amylyx Pharmaceuticals - rare disease focus
- Alexion / AstraZeneca - rare disease therapies
- Sangamo Therapeutics - rare disease gene therapy
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.